-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $50

Benzinga·08/07/2026 20:19:45
Listen to the news
Citigroup analyst Brendan Digan maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $45 to $50.